|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Planchard D, Popat S, Kerr K, Novello S,
Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD,
et al: Metastatic non-small cell lung cancer: ESMO clinical
practice guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 29 (Suppl 4):iv192–iv237. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schiller JH, Harrington D, Belani CP,
Langer C, Sandler A, Krook J, Zhu J and Johnson DH; Eastern
Cooperative Oncology Group, : Comparison of four chemotherapy
regimens for advanced non-small-cell lung cancer. N Engl J Med.
346:92–98. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Scagliotti GV, Parikh P, von Pawel J,
Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U,
Digumarti R, Zukin M, et al: Phase III study comparing cisplatin
plus gemcitabine with cisplatin plus pemetrexed in
chemotherapy-naive patients with advanced-stage non-small-cell lung
cancer. J Clin Oncol. 26:3543–3551. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Brahmer JR, Rodríguez-Abreu D, Robinson
AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A,
Cuffe S, et al: Health-related quality-of-life results for
pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC
(KEYNOTE-024): A multicentre, international, randomised, open-label
phase 3 trial. Lancet Oncol. 18:1600–1609. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Reck M, Rodríguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: Updated analysis of KEYNOTE-024: Pembrolizumab versus
platinum-based chemotherapy for advanced non-small-cell lung cancer
with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol.
37:537–546. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho
BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK,
Bondarenko I, et al: Pembrolizumab versus chemotherapy for
previously untreated, PD-L1-expressing, locally advanced or
metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised,
open-label, controlled, phase 3 trial. Lancet. 393:1819–1830. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Incorvaia L, Fanale D, Badalamenti G,
Barraco N, Bono M, Corsini LR, Galvano A, Gristina V, Listì A,
Vieni S, et al: Programmed death ligand 1 (PD-L1) as a predictive
biomarker for pembrolizumab therapy in patients with advanced
non-small-cell lung cancer (NSCLC). Adv Ther. 36:2600–2617. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
West H, McCleod M, Hussein M, Morabito A,
Rittmeyer A, Conter HJ, Kopp HG, Daniel D, McCune S, Mekhail T, et
al: Atezolizumab in combination with carboplatin plus
nab-paclitaxel chemotherapy compared with chemotherapy alone as
first-line treatment for metastatic non-squamous non-small-cell
lung cancer (IMpower130): A multicentre, randomised, open-label,
phase 3 trial. Lancet Oncol. 20:924–937. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gadgeel S, Rodríguez-Abreu D, Speranza G,
Esteban E, Felip E, Dómine M, Hui R, Hochmair MJ, Clingan P, Powell
SF, et al: Updated analysis from KEYNOTE-189: Pembrolizumab or
placebo plus pemetrexed and platinum for previously untreated
metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol.
38:1505–1517. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hadash-Bengad R, Hajaj E, Klein S, Merims
S, Frank S, Eisenberg G, Yakobson A, Orevi M, Caplan N, Peretz T,
et al: Immunotherapy potentiates the effect of chemotherapy in
metastatic melanoma-a retrospective study. Front Oncol. 10:702020.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Judd J and Borghaei H: Combining
immunotherapy and chemotherapy for non-small cell lung cancer.
Thorac Surg Clin. 30:199–206. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tseng CW, Hung CF, Alvarez RD, Trimble C,
Huh WK, Kim D, Chuang CM, Lin CT, Tsai YC, He L, et al:
Pretreatment with cisplatin enhances E7-specific CD8+
T-cell-mediated antitumor immunity induced by DNA vaccination. Clin
Cancer Res. 14:3185–3192. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Banchereau R, Leng N, Zill O, Sokol E, Liu
G, Pavlick D, Maund S, Liu LF, Kadel E III, Baldwin N, et al:
Molecular determinants of response to PD-L1 blockade across tumor
types. Nat Commun. 12:39692021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Saar M, Narits J, Mägi L, Aaspõllu H,
Vapper A, Kase M, Minajeva A, Vooder T, Tamm H, Buldakov M, et al:
Expression of immune checkpoint PD-1 in non-small cell lung cancer
is associated with tumor cell DNA-dependent protein kinase. Mol
Clin Oncol. 15:2112021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lavogina D, Lust H, Tahk MJ, Laasfeld T,
Vellama H, Nasirova N, Vardja M, Eskla KL, Salumets A, Rinken A and
Jaal J: Revisiting the resazurin-based sensing of cellular
viability: Widening the application horizon. Biosensors (Basel).
12:1962022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
European Medicines Agency: Tecentriq.
https://www.ema.europa.eu/en/medicines/human/EPAR/tecentriqNovember
11–2021
|
|
18
|
European Medicines Agency: Imfinzi.
https://www.ema.europa.eu/en/medicines/human/EPAR/imfinziNovember
11–2021
|
|
19
|
European Medicines Agency: Opdivo.
https://www.ema.europa.eu/en/medicines/human/EPAR/opdivoNovember
11–2021
|
|
20
|
European Medicines Agency: Keytruda.
https://www.ema.europa.eu/en/medicines/human/EPAR/keytrudaNovember
11–2021
|
|
21
|
Lavogina D, Laasfeld T, Vardja M, Lust H
and Jaal J: Viability fingerprint of glioblastoma cell lines: Roles
of mitotic, proliferative, and epigenetic targets. Sci Rep.
11:203382021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Aparecium. GPCR Workgroup UT; https://gpcr.ut.ee/aparecium.htmlDecember
19–2022
|
|
23
|
Noubissi FK, McBride AA, Leppert HG,
Millet LJ, Wang X and Davern SM: Detection and quantification of
γ-H2AX using a dissociation enhanced lanthanide fluorescence
immunoassay. Sci Rep. 11:89452021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hargadon KM, Johnson CE and Williams CJ:
Immune checkpoint blockade therapy for cancer: An overview of
FDA-approved immune checkpoint inhibitors. Int Immunopharmacol.
62:29–39. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Paz-Ares L, Luft A, Vicente D, Tafreshi A,
Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, et
al: Pembrolizumab plus chemotherapy for squamous non-small-cell
lung cancer. N Engl J Med. 379:2040–2051. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Leonetti A, Wever B, Mazzaschi G, Assaraf
YG, Rolfo C, Quaini F, Tiseo M and Giovannetti E: Molecular basis
and rationale for combining immune checkpoint inhibitors with
chemotherapy in non-small cell lung cancer. Drug Resist Updat.
46:1006442019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fucikova J, Kralikova P, Fialova A,
Brtnicky T, Rob L, Bartunkova J and Spísek R: Human tumor cells
killed by anthracyclines induce a tumor-specific immune response.
Cancer Res. 71:4821–4833. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nishio M, Barlesi F, West H, Ball S,
Bordoni R, Cobo M, Longeras PD, Goldschmidt J Jr, Novello S,
Orlandi F, et al: Atezolizumab plus chemotherapy for first-line
treatment of nonsquamous NSCLC: Results from the randomized phase 3
IMpower132 trial. J Thorac Oncol. 16:653–664. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Abbar B, De Castelbajac V, Gougis P,
Assoun S, Pluvy J, Tesmoingt C, Théou-Anton N, Cazes A, Namour C,
Khalil A, et al: Definitions, outcomes, and management of
hyperprogression in patients with non-small-cell lung cancer
treated with immune checkpoint inhibitors. Lung Cancer.
152:109–118. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Denis M, Duruisseaux M, Brevet M and
Dumontet C: How can immune checkpoint inhibitors cause
hyperprogression in solid tumors? Front Immunol. 11:4922020.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li J and Gu J: PD-L1 expression and EGFR
status in advanced non-small-cell lung cancer patients receiving
PD-1/PD-L1 inhibitors: A meta-analysis. Future Oncol. 15(14):
1667–1678. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang S, Bai X and Shan F: The progress
and confusion of anti-PD1/PD-L1 immunotherapy for patients with
advanced non-small cell lung cancer. Int Immunopharmacol.
80:1062472020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rodríguez-Abreu D, Powell SF, Hochmair MJ,
Gadgeel S, Esteban E, Felip E, Speranza G, De Angelis F, Dómine M,
Cheng SY, et al: Pemetrexed plus platinum with or without
pembrolizumab in patients with previously untreated metastatic
nonsquamous NSCLC: Protocol-specified final analysis from
KEYNOTE-189. Ann Oncol. 32:881–895. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Siddik ZH: Cisplatin: Mode of cytotoxic
action and molecular basis of resistance. Oncogene. 22:7265–7279.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Henriques AC, Ribeiro D, Pedrosa J,
Sarmento B, Silva PMA and Bousbaa H: Mitosis inhibitors in
anticancer therapy: When blocking the exit becomes a solution.
Cancer Lett. 440–441. 64–81. 2019.PubMed/NCBI
|
|
36
|
Zhang Y, Chen X, Gueydan C and Han J:
Plasma membrane changes during programmed cell deaths. Cell Res.
28:9–21. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
De Sousa Linhares A, Battin C, Jutz S,
Leitner J, Hafner C, Tobias J, Wiedermann U, Kundi M, Zlabinger GJ,
Grabmeier-Pfistershammer K and Steinberger P: Therapeutic PD-L1
antibodies are more effective than PD-1 antibodies in blocking
PD-1/PD-L1 signaling. Sci Rep. 9:114722019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lee HT, Lee JY, Lim H, Lee SH, Moon YJ,
Pyo HJ, Ryu SE, Shin W and Heo YS: Molecular mechanism of
PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and
durvalumab. Sci Rep. 7:55322017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mohiuddin M and Kasahara K: Cisplatin
activates the growth inhibitory signaling pathways by enhancing the
production of reactive oxygen species in non-small cell lung cancer
carrying an EGFR exon 19 deletion. Cancer Genomics Proteomics. 18
(3 Suppl):S471–S486. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Marín-Jiménez JA, Capasso A, Lewis MS,
Bagby SM, Hartman SJ, Shulman J, Navarro NM, Yu H, Rivard CJ, Wang
X, et al: Testing cancer immunotherapy in a human immune system
mouse model: Correlating treatment responses to human chimerism,
therapeutic variables and immune cell phenotypes. Front Immunol.
12:6072822021. View Article : Google Scholar : PubMed/NCBI
|
